Examining Emergent Biosolutions' failure to protect public health and public funds : hearing before the Select Subcommittee on the Coronavirus Crisis of the Committee on Oversight and Reform, House of Representatives, One Hundred Seventeenth Congress, first session, May 19, 2021.

Format:

Book

Government document

Author/Creator:

United States. Congress. House. Committee on Oversight and Reform. Select Subcommittee on the Coronavirus Crisis, author.

Language:

English

Subjects (All):

COVID-19 (Disease)--Vaccination--United States.

COVID-19 (Disease).

COVID-19 Pandemic, 2020-2023--United States.

COVID-19 Pandemic, 2020-2023.

Vaccines industry--Government policy--United States.

Vaccines industry.

Vaccines industry--Subsidies--United States.

Vaccines--United States.

Vaccines.

COVID-19 (Disease)--Vaccination.

Vaccines industry--Government policy.

Vaccines industry--Subsidies.

United States.

Genre:

Legislative hearings

Legislative hearings.

Physical Description:

1 online resource (iii, 44 pages)

Place of Publication:

Washington : U.S. Government Publishing Office, 2021.

Participant:

Hearing witnesses: Mr. Robert G. Kramer, President and Chief Executive Officer, Emergent BioSolutions, Inc.; Mr. Faud El-Hibri, Executive Chairman of the Board of Directors, Emergent BioSolutions, Inc..

Notes:

Access ID (govinfo): CHRG-117hhrg44686.

"Serial no. 117-23."

Date of hearing: 2021-05-19.

Description based on online resource; title from PDF title page (govinfo, viewed July 12, 2021).

Other Format:

Print version: United States. Congress. House. Committee on Oversight and Reform. Select Subcommittee on the Coronavirus Crisis. Examining Emergent Biosolutions' failure to protect public health and public funds

OCLC:

1259692367

Publisher Number:

44-686 (GPO jacket number)